Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion. [Phase 1]
Investigator-initiated Phase 1 study to evaluate the safety of combining CLS-015 with anti-CD-19 CAR-T cells in patients with diffuse large …
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma [Phase 2]
Phase 2 clinical trial update evaluating Relmacabtagene autoleucel in combination with sintilimab for relapsed/refractory B-cell lymphomas; …
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Communication Skills Intervention to Promote Transition Into Survivorship
This clinical trial update describes a communication skills intervention intended to help patients with Hodgkin lymphoma and diffuse large B…
-
FDA approval · 2026-01-16FDA Approved: ZYNLONTA — Supplemental Application (ADC Therapeutics America, Inc.)
The FDA approved a supplemental application for ZYNLONTA (loncastuximab tesirine) filed by ADC Therapeutics America, Inc., effectively updat…
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma [Phase 3]
A multicenter, prospective phase 3 randomized study evaluating decitabine added to R-CHOP as initial therapy for EBV-positive diffuse large …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) [Phase 1]
Phase 1 clinical trial update for ABBV-319 evaluating adverse events, change in disease activity, and pharmacokinetics in adults with relaps…
-
CLINICAL_TRIALS other · 2026-01-15Clinical Trial Update: Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL [Phase 1, Phase 2]
A Phase 1/2 study of E7777 for relapsed or refractory diffuse large B-cell lymphoma is suspended; no results are provided in this update.
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma [EARLY_Phase 1]
An open, dose-escalation early Phase 1 study of CAR-T cells targeting CD19 and CD20 for relapsed or refractory aggressive B-cell lymphoma is…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma [Phase 1, Phase 2]
Ongoing Phase 1/2 study evaluating ST-067 in combination with CD19-directed CAR T-cell therapy (Liso-cel) for relapsed/refractory diffuse la…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Glofitamab in Real Life
A real-world clinical trial of glofitamab for diffuse large B-cell lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1]
This is a Phase 1 trial evaluating anti-CD19 CAR-T cell therapy for relapsed or refractory non-Hodgkin lymphoma. The study is currently recr…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination of axicabtagene ciloleucel and glofitamab as second-line therapy for relapsed or refr…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors [NA]
A clinical trial update describing a study on implementing lifestyle-based survivorship care plans for lymphoma survivors.
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies [Phase 1]
A Phase 1 clinical trial evaluating UB-VV111 with and without rapamycin for relapsed/refractory CD19+ B-cell malignancies is currently recru…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma
This update describes a real-world data and sample collection study in frail or heavily pretreated diffuse large B-cell lymphoma patients, c…
-
CLINICAL_TRIALS trial_result · 2026-01-08Clinical Trial Update: Glofitamab Combined With CAR-T Therapy in R/R DLBCL [Phase 2]
Phase 2 clinical trial assessing glofitamab in combination with CAR-T therapy for relapsed/refractory diffuse large B-cell lymphoma; the stu…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: DALY II Japan/MB-CART2019.1 for DLBCL [Phase 2]
A Phase 2 trial (DALY II Japan/MB-CART2019.1) by Miltenyi Biomedicine is evaluating MB-CART2019.1 for diffuse large B-cell lymphoma in Japan…
-
CLINICAL_TRIALS other · 2026-01-08Clinical Trial Update: Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma [Phase 1]
Phase 1 clinical trial update on mosunetuzumab in combination with platinum-based salvage chemotherapy for relapsed/refractory aggressive B-…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma [Phase 1]
A Phase 1 study of KITE-197 for relapsed or refractory diffuse large B-cell lymphoma is currently active and not recruiting.
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Copanlisib Plus Venetoclax in R/R DLBCL [Phase 1, Phase 2]
A Phase 1/Phase 2 study conducted by the Dana-Farber Cancer Institute is evaluating the combination of copanlisib and venetoclax in relapsed…
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
This trial update reports on pharmacogenomics effects on the clearance of high-dose methotrexate in patients with diffuse large B-cell lymph…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL [Phase 2]
A phase 2 clinical trial is evaluating the feasibility and clinical efficacy of atezolizumab as consolidation therapy in high-risk diffuse l…
-
CLINICAL_TRIALS trial_result · 2026-01-05Clinical Trial Update: Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma [Phase 3]
This Phase 3 trial is investigating whether dexrazoxane can prevent heart damage caused by anthracycline chemotherapy in patients with Diffu…
-
CLINICAL_TRIALS trial_result · 2026-01-02Clinical Trial Update: Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy [NA]
A completed clinical trial studying the kinetics of circulating tumor DNA in patients with Diffuse Large B Cell Lymphoma treated with immuno…
-
CLINICAL_TRIALS research · 2026-01-02Clinical Trial Update: A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL) [Phase 2]
A Phase II trial tests rituximab with CC-99282 as front-line therapy for older frail patients with diffuse large B-cell lymphoma. The study,…